The Lock and Key of Medicine: Monoclonal Antibodies and the Transformation of HealthcareThe untold story of monoclonal antibodies--the molecular heroes of biotechnology that revolutionized the diagnosis and treatment of more than fifty major diseases This book is the first to tell the extraordinary yet unheralded history of monoclonal antibodies. Often referred to as Mabs, they are unfamiliar to most nonscientists, yet these microscopic protein molecules are everywhere, quietly shaping our lives and healthcare. Discovered in the mid-1970s in the laboratory where Watson and Crick had earlier unveiled the structure of DNA, Mabs have radically changed understandings of the pathways of disease. They have enabled faster, cheaper, and more accurate clinical diagnostic testing on a vast scale. And they have played a fundamental role in pharmaceutical innovation, leading to such developments as recombinant interferon and insulin, and personalized drug therapies such as Herceptin. Today Mabs constitute six of the world's top ten blockbuster drugs and make up a third of new introduced treatments. Lara V. Marks recounts the risks and opposition that a daring handful of individuals faced while discovering and developing Mabs, and she addresses the related scientific, medical, technological, business, and social challenges that arose. She offers a saga of entrepreneurs whose persistence and creativity ultimately changed the healthcare landscape and brought untold relief to millions of patients. Even so, as Marks shows, controversies over Mabs remain, and she examines current debates over the costs and effectiveness of these innovative drugs. |
Contents
1 Hunting for the Elusive Magic Bullet | 1 |
Patents Politics and Process | 25 |
3 Breakthroughs at the Bench | 47 |
4 The First Medical Applications | 69 |
Early Clinical Tests | 88 |
6 The Wild West of Antibody Commercialization | 110 |
7 The Challenge of Monoclonal Antibody Drugs | 139 |
A Renaissance for Mab Therapeutics | 159 |
Other editions - View all
Common terms and phrases
Anon anti antigens antisera approval Arthritis autoimmune available online bacteria Biology Biotech biotechnology Birndorf blood cells body bone marrow Cambridge Cambrosio and Keating Campath cancer cell line Celltech Centocor Centoxin César Milstein chimeric clinical trials cloning colleagues commercial Crohn’s disease Cuello culture diagnostic disease early fusion Genentech genes genetic helped Herzenberg Hubert Schoemaker human antibodies human Mabs hybridoma Hybritech Idec immune response immune system Immunology infections infliximab interferon Interview Jenny Murray Journal Köhler Koprowski laboratory leukemia Lonberg lymphocytes lymphoma Mab drugs Mab therapeutics Mabs Medical Medicine million Molecular Monoclonal Antibodies mouse MSTN murine Murray myeloma cell Neuberger patients percent phage pharmaceutical PNAS produce Mabs production protein purified reagents recombinant regulatory rituximab Royston Schoemaker scientists Secher sepsis Sept Sera Sera-Lab serum specific target technique therapy tion tissue transplant trastuzumab treatment tumor typing Vilček virus Waldmann Wistar